

**KPBMA**Korea Pharmaceutical and Bio-Pharma  
Manufacturers Association**MEDCITY**

# Building a bridge: UK/Korea Life Sciences

## Artificial Intelligence, Advanced Therapies and Access to Translational Medicine

InterContinental COEX, Gangnam, Seoul – Vivace, B1

16 April 2019, 14:00 – 18:30

한국제약바이오협회와 영국 Medcity 그리고 한국보건산업진흥원이 함께하는 한국-영국 생명과학 심포지움(AI, Advanced Therapies, Translational Medicine)에 초대합니다. 이번 심포지움은 영국의 캠브릿지, 옥스포드, 임페리얼컬리지, 킹스컬리지의 전문가들과 함께합니다.

- 13:30 등록
- 14:00 환영사 및 개최배경 소개
  - Simon Smith 대사, 주한영국대사관
  - 원희목 회장, 한국제약바이오협회
  - Gareth Davies 과학기술팀장, 주한영국대사관
- 14:30 런던/옥스포드/캠브릿지 생명과학 관련 연구 소개
  - Phil Jackson, MedCity 사업개발이사, 영국
- 15:00 기조연설: AI를 활용한 신약 후보물질 발굴
  - 한남식 인공지능연구센터장, 캠브릿지의과대학 밀너연구소
- 15:30 네트워킹 및 커피브레이크
- 16:00 Translational Medicine
  - James Naismith 연구소장, 옥스포드대학 로잘린프랭클린연구소
  - 고정민 교수, 아산병원 내분비내과
- 17:00 임페리얼컬리지의 연구현황 소개
  - Stephanie Morris 교수, 임페리얼컬리지 런던
- 17:30 Advanced Therapies : 면역항암제의 부상과 차세대 의약품
  - Farzin Farzaneh 교수, 킹스컬리지 런던
- 18:00 한국-영국 이노베이션 촉진방안 논의(패널토론)
- 18:30 마무리

**KhIDI**Korea Health Industry  
Development Institute



Simon Smith CMG was appointed Her Majesty's Ambassador to the Republic of Korea in 2018. Along with a number of other diplomacy positions, before moving to Korea, Simon acted as Ambassador to the UK in Austria and Ukraine.



Dr. Hee-Mok Won has been the Chairman and C.E.O of KPBMA since March, 2017. Based on his thorough knowledge and experience in the field of health care policy and academia, Dr. Won has been one of the international leaders in the health and pharmaceutical industry, contributing to domestic advancement into the global market.



Phil Jackson is Project Director at MedCity and is the go-to person for businesses wanting to find workspace, equipment, expertise, and funding, in the region. Previously, he held senior positions in Canadian healthcare; he led the development of the multi-million dollar Health Protection Agency and a re-design of Stroke prevention, treatment and rehabilitation services



Namshik Han is the Head of Computational Biology group at the Milner Therapeutics Institute in University of Cambridge. The group develops and applies cutting-edge computational methods, such as artificial intelligence and machine learning, fulfilling the global mission of identifying new or better therapies from the analysis of biological data.



Professor Jim Naismith is a world leading expert in structural biology, blending structural analysis, mechanistic study and developing new approaches to answer chemical problems in biology. He became Interim Academic lead at the Rosalind Franklin Institute in 2017 and will take up post as the first full Director of the Institute in June 2019.



Stephanie Morris is a life-sciences professional and currently heads the translational activities for academic discovery and innovation for the Faculty of Medicine at Imperial College, including early stage industry collaborations through to licensing and spin-outs. The ultimate goal is for market adoption of health and wellbeing technologies that make a real-world impact.



Farzin Farzaneh holds the Chair of Molecular Medicine at King's College London. He has published over 250 research articles and, since 2001, he has run a licensed GMP facility at King's College London for the development and production of cell and gene therapy based investigational medicinal products.

**To register for the event click [here](#).**